Annexon Biosciences, a clinical stage biopharmaceutical company focused on the development of novel therapeutics through inhibition of the classical complement pathway, announced on 12/19/18 that... read more
Annexon Biosciences, a clinical stage biopharmaceutical company focused on the development of novel therapeutics through inhibition of the classical complement pathway, announced on 12/19/18 that... read more
Versant Ventures announced on 12/17/18 that it raised USD100 million for a Canadian fund called Versant Voyageurs I. Voyageurs will be deployed across five to eight startup companies with Canadian... read more
Merck [NYSE:MRK] and privately held Antelliq Group announced on 12/14/18 that the companies have signed a definitive agreement under which Merck will acquire Antelliq from funds advised by BC... read more
Two programs (one in the US and one in the UK) offering life science companies lab space and access to capital and advisors made announcements about lab space for seed and early stage
... read more
